Evidence map›Paper›PMID 31088315›Full record

ArticleEpigenetics2019

Regulation of

Qianying Zhu, Lushan Yu, Zhiyuan Qin, Lu Chen, Haihong Hu, Xiaoli Zheng, Su Zeng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Epigenetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Drug metabolism and disposition: the biological fate of chemicals · 2022
    Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Qianying Zhua Institute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research , College of Pharmaceutical Sciences, Zhejiang University , Hangzhou , China.
Lushan Yua Institute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research , College of Pharmaceutical Sciences, Zhejiang University , Hangzhou , China.
Zhiyuan Qina Institute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research , College of Pharmaceutical Sciences, Zhejiang University , Hangzhou , China.ORCID 0000-0003-0824-5638
Lu Chena Institute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research , College of Pharmaceutical Sciences, Zhejiang University , Hangzhou , China.
Haihong Hua Institute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research , College of Pharmaceutical Sciences, Zhejiang University , Hangzhou , China.
Xiaoli Zhengb Hangzhou Cancer Institution , Hangzhou Cancer Hospital , Hangzhou , China.
Su Zenga Institute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research , College of Pharmaceutical Sciences, Zhejiang University , Hangzhou , China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Renal cell carcinoma (RCC) is a common malignant tumour affecting the urinary system, and multidrug resistance is one of the major reasons why chemotherapy for this type of cancer often fails. Previous studies have shown that loss of the human organic cation transporter OCT2 is the main factor contributing to oxaliplatin resistance in RCC, and that DNA hypermethylation and histone methylation play important roles in the transcriptional repression of

Indexed as

Drug Resistance, NeoplasmAcetylationCarcinoma, Renal CellCell Line, TumorDecitabineDown-RegulationEpigenesis, GeneticGene Expression Regulation, NeoplasticHistone DeacetylasesHistonesHumansKidney NeoplasmsOrganic Cation Transporter 2OxaliplatinPromoter Regions, GeneticProto-Oncogene Proteins c-mycDecitabineHDAC7 protein, humanHistone DeacetylasesHistonesMYC protein, humanOrganic Cation Transporter 2OxaliplatinProto-Oncogene Proteins c-mycSLC22A2 protein, humanVorinostatcombination therapyepigenetic regulationhistone acetylaionOCT2Renal cell carcinoma

Identifiers

PMID31088315
PMCPMC6615535

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.